The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | Phase II study of Durvalumab for patients with NSCLC
David Gandara, MD, from the University of California, Davis, CA discusses the S1400A Lung-Map trial (NCT02766335) at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland. This trial demonstrated the effect of durvalumab on patients with non-small cell lung cancer (NSCLC). Other trials like the MYSTIC trial (NCT02453282) are awaiting results regarding the use of durvalumab for the treatment of NSCLC.
